MHY4571, a novel diarylcyclohexanone derivative, exerts anti-cancer activity by regulating the PKA-cAMP-response element-binding protein pathway in squamous cell lung cancer
ConclusionsOur results imply that MHY4571 may be a potential drug candidate for squamous cell lung cancer treatment.
Source: Experimental Hematology and Oncology - Category: Cancer & Oncology Source Type: research
More News: Cancer | Cancer & Oncology | Carcinoma | Hematology | Lung Cancer | Non-Small Cell Lung Cancer | Squamous Cell Carcinoma | Study